Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

FDA Accepts Complete Response Submission Regarding the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

PHILADELPHIA, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed on July 31, 2012 with the U.S. Food and Drug Administration its complete...
August 08, 2012 15:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2012

Resources Directed at Ampligen® New Drug Application and Enhancements to Manufacturing Facility Continue Net Comprehensive Loss Reduced PHILADELPHIA, Aug. 8, 2012 (GLOBE NEWSWIRE) --...
August 01, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Files Complete Response With the FDA Regarding Its Ampligen(R) New Drug Application for Chronic Fatigue Syndrome

PHILADELPHIA, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") filed yesterday with the U.S. Food and Drug Administration its complete response to...
July 18, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen(R) to Treat Chronic Fatigue Syndrome

PHILADELPHIA, July 18, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it has submitted a new drug application to ANMAT (Administracion...
July 11, 2012 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma and the FDA Reach Agreement on Filing Requirements for the Company's Complete Response in Support of Ampligen(R) New Drug Application for Chronic Fatigue Syndrome Treatment

PHILADELPHIA, July 11, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") recently met with representatives of the U.S. Food and Drug Administration (the...
May 07, 2012 16:35 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2012

PHILADELPHIA, May 7, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced its financial results for the three months ended March 31, 2012. The net loss for the period (including...
April 30, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Test of Ampligen(R) With FluMist

PHILADELPHIA, April 30, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx"), announced that Ampligen®, an experimental immunotherapeutic, has been...
March 26, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)

Incidence of NABs Induced Against Natural IFNs, Such as Alferon N Injection®, Was Very Low (<0.2%) and Significantly Less Than for Recombinant IFNs PHILADELPHIA, March 26, 2012 (GLOBE...
March 20, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma, Inc. to Host 2011 Year End Conference Call on Thursday, March 22, 2012

PHILADELPHIA, March 20, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, March 22, 2012 at 10:00 a.m....
March 19, 2012 08:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Publishes Data on the Bioactivity of Ampligen(R) in Chronic Fatigue Syndrome ("CFS")

PHILADELPHIA, March 19, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced the publication of a peer-reviewed article providing the results...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right